Step up to the plate and save a life

Hoxworth Blood Center and the Cincinnati Reds team up to save lives

Hoxworth Blood Center, University of Cincinnati, and the Cincinnati Reds are once again teaming up to knock summer blood donations out of the park.

All blood and platelet donors who make a lifesaving donation at any of Hoxworth’s seven Neighborhood Donor Centers between June 2 and June 23 will receive an exclusive Cincinnati Reds “Donor” Jersey (while supplies last).

“Summertime is a historically difficult time for blood banks across the nation, which means it’s time for the greater Cincinnati community to step up to the plate and donate,” says Jackie Marschall, Hoxworth spokesperson. “We are so grateful for our partnership with the Cincinnati Reds for lending their support and encouraging their fans to donate blood this summer.”

Hoxworth is the sole supplier of blood products to more than 30 hospitals in the Tristate area and needs at least 450 donors daily to meet the demand of those hospitals. 

Hoxworth officials expect this promotion to be extremely popular and encourage making appointments as early as possible. Individuals can schedule at hoxworth.org or by calling 513-451-0910. 

About Hoxworth:
Hoxworth Blood Center, University of Cincinnati, was founded in 1938, and serves more than 30 hospitals in 18 counties in Southwestern Ohio, Northern Kentucky and Southeastern Indiana. Annually, Hoxworth collects more than 100,000 units of blood from local donors to help save the lives of patients in area hospitals. Hoxworth Blood Center: Saving Lives Close to Home. 

Related Stories

2

What's behind the mysterious rise of migraines?

January 5, 2026

Weather patterns such as extreme heat and storm conditions have been linked to migraine attacks, and research shows those environmental conditions are becoming more common. As National Geographic recently reported, one of the leading theories behind this mysterious rise is that climate change may be playing a role.

3

Top six 2025 nephrology drug approvals

January 5, 2026

“2025 has been a landmark year for kidney disease therapeutics, marked by a comprehensive slate of FDA approvals covering endothelin-receptor blockade, complement inhibition, GLP-1-based metabolic protection, and B-cell-directed therapy,” Prakash Gudsoorkar, MD, associate professor of clinical medicine at the University of Cincinnati College of Medicine and staff nephrologist at UC Health, recently told MedCentral.